Introduction
Squamous cell carcinoma of the head and neck (SCCHN) is the most common epithelial malignancy arising in the upper aerodigestive tract, encompassing the oral cavity, oropharynx, hypopharynx, pharynx and larynx. The American Cancer Society estimates that there are over 40 000 new cases of SCCHN in the United States every year (Cancer Stats, 1990 ) and more than two-thirds of these cases will present with advanced disease (stage III or IV) (AJCC, 1983) . The prevalence of SCCHN is increasing worldwide (Mashberg, 1993) . In many developing countries, the increasing prevalence of SCCHN has had a dramatic eect on public health (Boyle et al., 1992) . Although SCCHN represents only 3 ± 4% of all cancers in the US, the adverse impact of SCCHN on health quality can be dramatic: for example, from 1973 to 1987 there was a 6% annual increase in pharyngeal cancer among black men, which contributed to an overall increase in mortality of 2% per year for pharyngeal cancer (US Dept HHS, 1991) .
Improved techniques in surgery, radiation and chemotherapy have increased the local control of SCCHN but the overall survival rates have not changed signi®cantly in 25 years (Dimery and Hong, 1993) . Despite optimal therapy, the overall survival rate is poor, with 40% 5-year survival for those with resectable tumors and 20% for those whose tumors are not amenable to excision (Dimery and Hong, 1993) . Half of those patients with advanced disease will go on to develop local recurrences and 30% or more will develop distant metastasis (Hong and Bromer, 1983) .
If patients do survive their primary SCCHN, studies have shown that there is a constant and continuing risk, from 2.7 ± 4% per year, of second primary tumor (i.e. aerodigestive tumors) formation each year following initial treatment (Jovanovich et al., 1994) . The probability of a second malignancy arising within 5 years after the initial tumor presentation can reach 22% (Dhooge et al., 1998) . Few treatment modalities are available to patients with recurrent head and neck cancer, and those who develop a second malignancy have only a 25% 5-year survival rate (Larson et al., 1990) . Chemotherapy is generally employed in advanced cases but the response rates average only 25 ± 40% with overall survival being measured in months (Dimery and Hong, 1993) . Thus, it is imperative that new treatment modalities are developed to increase the long-term survival of patients with SCCHN. Increasing our understanding of the biology of head and neck carcinogenesis will facilitate the design of therapies that speci®cally target head and neck tumor cells.
Field cancerization and multistep carcinogenesis in SCCHN
It has been estimated that dietary and smoking habits contribute to at least 70% of all cancer deaths (Castigliano, 1968) . Although the role of tobacco and alcohol consumption in the etiology of SCCHN is well accepted, the genetic alterations that lead to head and neck cancer formation are incompletely understood. In fact, although 490% of SCCHN patients have a history of tobacco and alcohol exposure, the vast majority of individuals who smoke and drink do not develop SCCHN. The tendency of the upper aerodigestive tract epithelium to undergo transformation in certain patients, and not others, when exposed to these agents, probably re¯ects genetic alterations in the regional mucosa (Rubin Grandis et al., 1998b) . The high rate of development of second malignancies in the head and neck underscores the`condemned' nature of the entire mucosa.`Field cancerization' has been proposed to explain the increased risk of transformation of the entire aerodigestive tract mucosa (Slaughter, 1946) .
The development of invasive cancer likely involves a step-wise progression through increasing degrees of dysplasia that result from the accumulation of genetic alterations. According to this theory, tumors grow by the process of clonal evolution driven by mutations, where multiple`hits' (mutations) on a cell are needed for cancer to develop (Vogelstein and Kinzler, 1993) . Applying this model to SCCHN, exposure to tobacco carcinogens stimulates the accumulation of alterations in the aerodigestive tract, facilitating the development of both the primary malignancy and subsequent secondary malignancies. Even normally appearing mucosa may have accumulated premalignant genetic changes that condemn' it to the formation of cancer. Identi®cation of these early genetic alterations in the tissue prior to cancer formation would enhance our understanding of the biology of squamous epithelial carcinogenesis.
TGF-a and EGFR in SCCHN
The growth and dierentiation of many cells, including upper aerodigestive tract epithelial cells is regulated, in part, by growth factors (James and Bradshaw, 1984) . When a cell acquires the ability to produce both a growth factor and its receptor that stimulates its own proliferation, an autocrine regulatory pathway may develop, resulting in uncontrolled growth. The acquisition in vitro of such an autocrine pathway has enabled cells of several lineages to be transformed from the normal to malignant phenotype (Roberts and Sporn, 1985) . Examples of autocrine growth pathways in cancer include gastrin-releasing peptide (GRP)/neuromedin B and GRP-receptor in lung cancer (Siegfried et al., 1993 (Siegfried et al., , 1997 DeMichele et al., 1994) , ®broblast growth factor (bFGF) and FGF-receptor (FGFR-1) in melanoma (Becker et al., 1989 (Becker et al., , 1992 and HER2-neu in breast cancer (for review see Earp et al., 1995) .
Members of the EGFR family have been implicated in the growth of a variety of human carcinomas. Overexpression of EGFR has been detected in tumors and cell lines established from patients with SCCHN (Ozanne et al., 1986; Maxwell et al., 1989; Kawamoto et al., 1991) . Transforming growth factor-a (TGF-a), an EGFR ligand, is also upregulated in tumor systems, including SCCHN (Partridge et al., 1989; Yoshida et al., 1990) . Although EGFR gene ampli®cation has been reported in selected SCCHN cell lines (Yamamoto et al., 1986; Weichselbaum et al., 1989; Ishitoya et al., 1989) evidence suggests that the upregulation detected at both the mRNA and protein levels cannot be accounted for by gene dosage alone (Eisbruch et al., 1987) . We previously demonstrated that this increase in TGF-a/ EGFR expression occurs primarily at the level of activated gene transcription and can be modi®ed by retinoic acid treatment (Rubin Grandis et al., 1996a) . We and others have found that this increase in EGFR expression is accompanied by an elevation of TGF-a production, thus providing an indirect evidence of an autocrine growth pathway (Todd et al., 1989; Rubin Grandis et al., 1996b) . We further demonstrated that in histologically normal mucosa specimens from patients with SCCHN, TGF-a and EGFR mRNA and protein levels are upregulated compared with normal control mucosa from patients without SCCHN, suggesting that activation of TGF-a/EGFR gene transcription is an early event in SCCHN carcinogenesis (Rubin Grandis et al., 1996b) . Expression levels of TGF-a and EGFR in the primary tumor also appear to be signi®cantly associated with adverse outcome, thus emphasizing the biological importance of this autocrine growth pathway in SCCHN progression (Rubin Grandis et al., 1998c) . In this study, levels of TGF-a were highly correlated with EGFR levels in the primary SCCHN tumor. Survival analysis demonstrated that TGF-a/EGFR expression was linked to decreased disease-speci®c survival, independent of cervical lymph node metastasis. Therefore, elucidating the mechanism of TGF-a/EGFR signaling in SCCHN may facilitate the design of novel treatment strategies which target this pathway.
EGFR targeting in SCCHN
The importance of TGF-a/EGFR autocrine signaling in SCCHN makes it an ideal target for novel therapeutic strategies. Treatment with EGFR antisense constructs has been shown to inhibit cancer cell growth and block transformation when transfected into cells in vitro (De Giovanni et al., 1996; Moroni et al., 1992) . We previously demonstrated that SCCHN cells treated with antisense oligonucleotides targeting TGF-a produced less TGF-a protein and were growth inhibited, whereas normal mucosal epithelial cells from patients without SCCHN were not aected by TGF-a antisense oligonucleotide treatment (Rubin Grandis et al., 1998b) . Targeting EGFR using either antisense oligonucleotides, monoclonal antibodies to the ligandbinding domain, or an EGFR-speci®c tyrosine kinase inhibitor all decreased proliferation of SCCHN cells without aecting the growth of normal mucosal epithelial cells (Rubin Grandis et al., 1997) . Extending our in vitro observations to a head and neck tumor model, we demonstrated anti-tumor ecacy following treatment of established tumor xenografts with an EGFR antisense expression construct (He et al., 1998) . These results suggest that TGF-a and EGFR are important for SCCHN cell proliferation but not for normal mucosal epithelial cell growth. Thus, strategies that target EGFR and/or TGF-a may speci®cally be directed against SCCHN cells with minimal eects on normal epithelial cells.
EGFR signaling and STAT proteins
The precise method by which TGF-a and other growth factor-induced surface signals are transmitted to the nucleus to modulate cell growth are only partially understood. Several potential EGFR signaling pathways have been described including Ras/MAP kinase, phosphatidylinositol-3-kinase and phospholipaseC-g (for review see Ulrich et al., 1990; Sharif et al., 1994; Carpenter, 1992) . However, there is little evidence that targeting these downstream molecules results in inhibition of proliferation. Many investigators have demonstrated that growth factors including EGF, TGF-a and platelet-derived growth factor can activate members of the STAT family, including Stat1 and Stat3 (Hernandez-Sotomayor et al., 1992; Kumar et al., 1995; Darnell, 1997; Ihle, 1996) .
An emerging literature suggests that STAT signaling may play a critical role in cancer formation and progression (for review see Garcia and Jove, 1998) . EGF has been shown to activate Stat1 and Stat3 in EGFR-overexpressing cells (Zhong et al., 1994; Park et al., 1996; Sadowski et al., 1993) . There is constitutively elevated tyrosine phosphorylation and DNA-binding activity of Stat3 in ®broblasts stably transformed by the Src oncoprotein . Ras-stimulated intestinal cells have constitutively activated Stat3 and this Stat3 activation is suppressed by EGFR-speci®c kinase inhibitors (Zushi et al., 1998) . Furthermore, data from transient transfection experiments in HeLa cells, using c-fos promoters lacking the STAT regulatory element c-sis-inducible element, indicate that this element may play a role in the induction of c-fos by EGF in these cells (Leaman et al., 1996) . Increased activation of Stat3 has been observed in a wide variety of human malignancies including breast cancer and breast cancer-derived cell lines (Watson and Miller, 1995; Garcia et al., 1997; Sartor et al., 1997) .
Growth factor receptors such as EGFR, that have an intrinsic tyrosine kinase, mediate STAT phosphorylation in a JAK-independent manner (Ihle, 1996) . The EGFR contains a cytoplasmic domain with protein tyrosine kinase activity. In response to ligands including TGF-a, EGFRs dimerizes and become phosphorylated on multiple tyrosine residues (Figure 1 ). These phosphotyrosines allow the activated EGFR to recruit STATs to cytoplasmic tyrosine residues including Y1068 and Y1086, thus activating STATs (Coer et al., 1995) . The speci®city of Y1068 and Y1086 for Stat3 recruitment is incompletely understood as others have shown that EGF or amphiregulin-induced activation of STAT is critically dependent on the receptor's intrinsic tyrosine kinase, but can occur independently of the cytoplasmic EGFR tyrosine phosphorylation sites (David et al., 1996) . Direct interaction between STAT protein src-homology 2 (SH2) domains and the activated EGFR leads to STAT phosphorylation. The activated STAT then forms dimers and translocates to the nucleus where it binds to DNAresponse elements in promoter regions, thus regulating growth factor/cytokine-directed gene expression (Zhong et al., 1994; Ihle, 1996; Darnell, 1997) .
TGF-a and EGFR are linked to constitutive Stat3 activation in SCCHN
To determine if TGF-a/EGFR-induced proliferation was linked to STAT signaling in SCCHN, we examined constitutive and TGF-a-stimulated activation of Stat1 and Stat3 in SCCHN cell lines and patient tissues. EMSAs using the duplex oligonucleotide, high anity serum inducible element (hSIE), speci®c for Stat1 and Stat3, revealed constitutive and TGF-a-induced activation predominantly of the SIF-A complex (Stat3 homodimer) and SIF-B complex (Stat3 and Stat1 heterodimer) in SCCHN cells compared to normal mucosal epithelial cells (Rubin Grandis et al., 1998d) . The presence of Stat3 and Stat1 in the SIF complexes was veri®ed with supershift analysis and DNA anity prui®cation studies. Immunoblotting with Stat1 or Stat3 antisera demonstrated an increase in Stat3 but not Stat1 protein expression levels in SCCHN cell lines compared with normal mucosal epithelial cells (Rubin Grandis et al., 1998d) . This increase in Stat3 activation was associated with increased Stat3 tyrosine phosphorylation (Rubin Grandis et al., 1998d) .
Figure 1 TGF-a/EGFR/Stat3 autocrine signaling pathway. Binding of TGF-a to EGFR induces phosphorylation on multiple tyrosine residues. Stat3 is recruited to EGFR cytoplasmic tyrosine residues Y1068 and Y1086 via src-homology (SH2) domains. Stat3 is then phosphorylated and forms homodimers which translocate to the nucleus binding to DNA-response elements (soluble inducible element [SIE]) in promoter regions, thus regulating gene expression EMSA analysis for Stat3 DNA binding activity in tissue samples from SCCHN patients demonstrated 8 ± 10-fold increased levels of constitutively activated Stat3 in both the tumor and in the histologically normal mucosa from SCCHN patients, compared with levels in the normal mucosa from controls without cancer (Rubin Grandis et al., 1999) . As in the SCCHN cell lines, SIF-A (Stat3 homodimer) and SIF-B (Stat1 and Stat3 heterodimer) were the predominant complexes formed. This increase in constitutive Stat3 activation in tissue specimens from patients with SCCHN was also associated with an increase in both Stat3 protein expression and Stat3 tyrosine phosphorylation when compared to mucosal specimens from controls (Rubin Grandis et al., 1999) .
To verify that activated Stat3 was derived from the epithelial cells, we performed in situ hybridization on tissue sections using 35 S-methionine-labeled hSIE (Hierholzer et al., 1998) . High-powered microscopy demonstrated increased activated Stat3 at the tumor/ stromal interface and that the cells containing activated Stat3 were epithelial cells and not tumor-in®ltrating lymphocytes (Rubin Grandis et al., 1999) . Tissue staining with a phosphotyrosine-speci®c anti-Stat3 antibody demonstrated phosphorylated Stat3 only in the basal epithelial layer in normal mucosa from controls without SCCHN. In contrast, phosphorylated Stat3 was detected throughout the entire epithelium in histologically normal mucosa from patients with SCCHN and phospho-Stat3 was overexpressed in the tumor (Rubin- Grandis et al., 1999) (Figure 2 ). Given the potentially`condemned' nature of even histologically normal mucosa in patients with SCCHN due tò ®eld cancerization', the ®nding of increased Stat3 activation and phosphorylated Stat3 levels in the histologically normal surrounding mucosa suggests that Stat3 activation is an early alteration in SCCHN carcinogenesis. Analyses of head and neck lesions for genetic alterations at major chromosomal loci have demonstrated increased allelic loss progressing from dysplasia to carcinoma in situ to invasive cancer, further supporting the genetic basis for`®eld cancerization' (Figure 3) (Califano et al., 1996) .
To determine the association between TGF-a/EGFR stimulation and Stat3 activation, we blocked TGF-a/ EGFR signaling with either an EGFR-speci®c tyrosine kinase inhibitor (PD153035) (Bos et al., 1997; Fry et al., 1994) or a TGF-a-neutralizing antibody (Rubin Grandis et al., 1998b) . Abrogation of TGF-a or EGFR resulted in decreased constitutive Stat3 activation suggesting that Stat3 activation is linked to TGF-a/ EGFR signaling in vitro. To explore such an association in vivo, an EGFR antisense gene therapy construct previously demonstrated to inhibit EGFR expression and SCCHN tumor growth (He et al., 1998) was injected into SCCHN xenografts. EMSAs demonstrated a decrease in constitutive Stat3 activation in tumors treated with EGFR antisense DNA plus liposomes when compared with tumors treated with liposomes alone (Figure 4 ). These cumulative results suggest that Stat3 is constitutively activated in SCCHN as a result of TGF-a/EGFR signaling. Furthermore, this activation appears to be associated both with an increase in Stat3 protein expression and an increase in Stat3 tyrosine phosphorylation.
Stat3 activation is important for TGF-a/EGFR-mediated SCCHN cell growth
To determine if constitutive Stat3 activation was critical for SCCHN proliferation, two dierent strategies of targeting Stat3 signaling were employed. First, Grandis et al., 1998d) . Clones expressing either mutant form of Stat3 (3F or 3D) failed to proliferate while cells stably transfected with the mutant form of Stat1 (1F) were not growth inhibited (Rubin Grandis et al., 1998d) .
A second strategy utilized phosphothioated antisense oligonucleotides targeting the translation start sites of Stat3 and Stat1 mRNA. Treatment of SCCHN cell lines with Stat3 antisense oligonucleotides resulted in signi®cant growth inhibition while treatment with Stat1 antisense oligonucleotides did not inhibit SCCHN cell proliferation (Rubin Grandis et al., 1998d) . In both dominant negative and antisense oligonucleotides experiments, a decrease in Stat3 activation was veri®ed by EMSA analysis. These results suggest that constitutive activation of Stat3 is critical for EGFR-mediated SCCHN growth and that Stat3 may serve as an oncogene in head and neck cancer (Bromberg et al., 1999) .
Stat3 antisense therapy induces apoptosis in SCCHN in vivo
To further elucidate the role of Stat3 activation in SCCHN progression in vivo, a Stat3 antisense construct was generated by cloning a Stat3 antisense or sense oligonucleotide sequence into a modi®ed U6 expression vector (He et al., 1998) . The Stat3 antisense (or sense) construct was inoculated into established SCCHN xenografts in combination with DC-chol liposomes. EMSAs performed using extracts from tumors injected with the Stat3 antisense construct had signi®cantly decreased Stat3 activation when compared with SCCHN xenografts treated with the Stat3 sense construct plus liposomes or with liposomes alone (Rubin Grandis et al., 1999) .
Emerging evidence suggests that Stat3 inhibits apoptosis by modulating apoptotic regulatory proteins Bromberg et al., 1999 ). Stat3 appears to be an important antiapoptotic mediator (Zushi et al., 1998; Niu et al., 1999) . A Stat3 dominant negative mutant introduced into rasstimulated intestinal epithelial carcinoma cells abolished resistance to apoptosis and reduced expression of Bcl-2 and Bcl-x L proteins (Zushi et al., 1998) . Stat3 has been shown to regulate transcription from the bclx promoter and cells transformed by constitutively active Stat3 have elevated levels of Bcl-x L mRNA. Activation of endogenous Stat3 by v-Src induces bcl-x gene expression 5 ± 20-fold over basal levels in transfected NIH3T3 cells . Additionally, a highly conserved 600 bp region of human and mouse bcl-x genes harbors multiple Stat3 binding sites, also called acute phase response elements or APRE sequences (Wegenka et al., 1993; Seidel et al., 1995) .
When we treated SCCHN xenografts with Stat3 antisense gene therapy and stained the tumors for DNA fragmentation (ApopTag), there was a twofold increase in the rate of apoptosis in the tumors treated with Stat3 antisense DNA plus liposomes compared with tumors treated with Stat3 sense DNA plus liposomes (Rubin Grandis et al., 1999 (He et al., 1998) . The position of the SIF-A complex (Stat3 homodimer) is indicated on the right was speci®c. Activation of genes that can stimulate proliferation or block apoptosis may facilicate tumor progression. Our ®ndings of increased tumor apoptosis associated with decreased Bcl-x L protein expression following treatment with Stat3 antisense gene therapy supports an interaction between Stat3 and bcl-x gene expression which may regulate apoptosis.
Conclusion
The carcinogen-induced alterations in the mucosa of the upper aerodigestive tract, which facilitate tumor formation, are incompletley understood. TGF-a/EGFR autocrine signaling appears to play an important role in head and neck carcinogenesis. Overexpression of the ligand and receptor is found in tumors, premalignant lesions and normal appearing epithelium from head and neck cancer patients compared with controls.
Identi®cation of aberrant TGF-a/EGFR regulation in premalignant tissues suggests that activation of TGF-a/ EGFR gene transcription is an early event in head and neck tumorigenesis and may serve as a preventive or therapeutic target. Strategies which downmodulate TGF-a or EGFR inhibit SCCHN cell proliferation and abrogate Stat3 activation. Targeting Stat3 in vitro, using several methods, blocks SCCHN cell growth. Results of in vivo studies support the role of Stat3 as an oncogene, which is activated early in SCCHN carcinogenesis. Moreover, abrogation of Stat3 function leads to increased apoptosis and speci®c downmodulation of Bcl-x L expression in head and neck tumors. Continued eorts to increase our understanding of the molecular mechanisms of EGFR-mediated Stat3 signaling in head and neck carcinogenesis, should facilitate the design of novel strategies which interfere with this growth-promoting, anti-apoptotic pathway.
